On February 18, 2026 Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, reported that Keros’ President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will present at the following healthcare conferences:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Oppenheimer 36th Annual Healthcare Life Sciences Conference
•Date and Time: Wednesday, February 25, 2026 at 11:20 a.m. Eastern time
•Link: https://event.summitcast.com/view/CTtthLh2Bi2D9aYoKpvtEv/V8otRzLTXb58JhbhcNWND2
•Format: Corporate Presentation
TD Cowen 46th Annual Health Care Conference
•Date and Time: Tuesday, March 3, 2026 at 9:50 a.m. Eastern time
•Link: https://event.summitcast.com/view/9z5g2VrV6e6rbCqQgDRoHA/gAsAzarzXsTWnurjwhWYFM
•Format: Fireside Chat Presentation
Leerink Partners Global Healthcare Conference
•Date and Time: Tuesday, March 10, 2026 at 1:00 p.m. Eastern time
•Link: https://event.summitcast.com/view/mT9poctHDNthc6b89WqVjf/4HAHET37grTuDD8oiMF2x7
•Format: Fireside Chat Presentation
For each presentation, an archived replay will be accessible in the Investors section of the Keros website at View Source for up to 90 days following the conclusion of each event.
(Press release, Keros Therapeutics, FEB 18, 2026, View Source [SID1234662754])